A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

Condition:   HER2-negative Breast Cancer Interventions:   Drug: AZD9833;   Drug: Fulvestrant Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials